These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 21809181

  • 1. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A, Salazar J.
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [Abstract] [Full Text] [Related]

  • 2. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 3. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ, Smith SM, Choksi R.
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [Abstract] [Full Text] [Related]

  • 4. [The future of renin inhibition].
    Uresin AY, Baran E.
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [Abstract] [Full Text] [Related]

  • 5. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
    Doulton TW, MacGregor GA.
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K.
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [Abstract] [Full Text] [Related]

  • 8. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
    Zeymer U, Dechend R, Deeg E, Kaiser E, Senges J, Pittrow D, Schmieder R, 3A Registry Investigators.
    Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
    [Abstract] [Full Text] [Related]

  • 9. [Renin inhibition and the kidney].
    Ecder T.
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [Abstract] [Full Text] [Related]

  • 10. [Advantages and limitations of renin inhibition with aliskiren].
    Azizi M, Frank M, Steichen O, Blanchard A.
    Ann Pharm Fr; 2011 May; 69(3):142-50. PubMed ID: 21570538
    [Abstract] [Full Text] [Related]

  • 11. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [Abstract] [Full Text] [Related]

  • 12. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 13. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB.
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [Abstract] [Full Text] [Related]

  • 14. Aliskiren in the treatment of hypertension and organ damage.
    Riccioni G.
    Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED, Preddie DC.
    Ethn Dis; 2002 Feb; 12(4):S3-49-52. PubMed ID: 12477155
    [Abstract] [Full Text] [Related]

  • 16. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V, Buksa M, Loza V, Kulic M.
    Med Arh; 2009 Feb; 63(6):343-9. PubMed ID: 20380117
    [Abstract] [Full Text] [Related]

  • 17. Managing cardiovascular and renal risk: the potential of direct renin inhibition.
    Sever PS, Gradman AH, Azizi M.
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):65-76. PubMed ID: 19502253
    [Abstract] [Full Text] [Related]

  • 18. Aliskiren: the first direct renin inhibitor available for clinical use.
    Morganti A, Lonati C.
    J Nephrol; 2011 Jun; 24(5):541-9. PubMed ID: 21786226
    [Abstract] [Full Text] [Related]

  • 19. Aliskiren, the future of renin-angiotensin system blockade?
    Uresin Y, Mehtar Bozkurt M, Sabirli S, Ozunal ZG.
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914
    [Abstract] [Full Text] [Related]

  • 20. [Is there a need for direct renin inhibitors?].
    Grossman E.
    Harefuah; 2008 Mar; 147(3):216-7, 278. PubMed ID: 18488862
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.